Overview
JAK-STAT-GO: Personalized, Targeted Therapy Options for Your IBD Patients in Seven Minutes or Less
Complimentary CME Dinner Symposium
Registration is closed for this activity.
Changing guidelines. New therapies. Busy practices and limited time. How can clinicians be assured they have the most up-to-date information for improving their patients’ outcomes? This fast-paced style dinner symposium led by leading experts in the field, offers short, concise presentations in an exciting and memorable Japanese-style CME format where 20 slides are advanced every 20 seconds, encompassing the latest in JAK-STAT guideline-based diagnosis and management paradigms for the treatment of IBD. Can you keep up?
This activity is intended for gastroenterologists, and other allied health care professionals interested in the JAK/STAT signaling pathway and applications to treatment of IBD.
Clinicians who treat patients with inflammatory disease such as IBD need to be updated on new and emerging therapies that will lead to individualized treatment and improved outcomes. Specifically, clinicians require education surrounding the role of the JAK/STAT signaling pathway in immune mediated diseases, up-to-date knowledge of the efficacy and safety of investigational JAK inhibitors, and the role of new and emerging JAK inhibitors in the treatment paradigm in IBD.
Upon completion of this activity, participants will be able to:
• Discuss the role of the JAK/STAT signaling pathway in the pathogenesis of IBD and the rationale for inhibition
• Compare and contrast the cytokine pathways targeted by available and emerging JAK inhibitors in IBD
• Interpret the clinical trial efficacy and safety data of JAK inhibitors investigated for Crohn’s disease and ulcerative colitis
• Identify IBD patients who require a change in therapy
• Discuss the role of the JAK/STAT signaling pathway in the pathogenesis of IBD and the rationale for inhibition
• Compare and contrast the cytokine pathways targeted by available and emerging JAK inhibitors in IBD
• Interpret the clinical trial efficacy and safety data of JAK inhibitors investigated for Crohn’s disease and ulcerative colitis
• Identify IBD patients who require a change in therapy
Hilton San Diego Bayfront Hotel
Sapphire Ballroom IJKMNO (Level 4)
One Park Boulevard
San Diego, CA 92101 USA
Click here to view location map
Sapphire Ballroom IJKMNO (Level 4)
One Park Boulevard
San Diego, CA 92101 USA
Click here to view location map
6:00 PM | Dinner and Onsite Registration |
6:15 PM | Introductions and Certification Information |
6:20 PM | What’s New in IBD Care? Choosing the Target—and Hitting the Bullseye |
6:45 PM | Everything You Wanted to Know About JAK/STAT *But Were Afraid to Ask |
7:10 PM | JAK for Joints and Guts Panel Discussion with ARS |
7:35 PM | Clinical Trials, Populations, and Safety |
8:00 PM | Questions and Answers |
Supported by an educational grant from Gilead Sciences, Inc.
CHAIRPERSON
Bruce Sands, MD, MS
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY
Bruce Sands, MD, MS
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, NY
FACULTY
Joel Pekow, MD
Assistant Professor of Medicine, Section of Gastroenterology, Hepatology, and Nutrition
University of Chicago Medicine and Biological Sciences
Chicago, IL
Thomas Ullman, MD
Chief, Division of Gastroenterology
Montefiore Medical Center/Albert Einstein College of Medicine
New York, NY
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CE activity.
The following financial relationships have been provided:
Bruce Sands, MD, (Chair)
Consulting Agreements: AbbVie, Allergan, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Ferring Pharmaceuticals, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Lilly, Otsuka, Pfizer, Inc., Synergy Pharmaceuticals Inc., Takeda, Theravance Biopharma, TiGenix
Grant/Research Support: Celgene
Honoraria Recipient: Takeda
Joel Pekow, MD, (Faculty)
Advisory Board: Janssen and Pfizer, Inc.
Consulting Agreements: Verastem
Grant Support: Takeda and AbbVie
Thomas Ullman, MD, (Faculty)
Advisory Board: Pfizer, Inc.
Honoraria Recipient: Janssen
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Tofacitinib, peficitinib, filgotinib, upadacitinib, and other JAK inhibitors under investigation for IBD
Guidelines require that participants in CME/CE activities be made aware of all financial relationships that may be perceived as affecting the presentation of the faculty member. ACHL ensures that all faculty and staff involved in the planning, development, and implementation of ACHL activities disclose relevant financial relationships and that conflicts of interest are resolved before the CME/CE activity occurs. Complete information will be provided to participants prior to the start of the educational activity.
This program is not affiliated with Digestive Disease Week®. Satellite events are complimentary to all DDW® attendees.
To receive credit, participants are required to participate in the live activity and complete the posttest and evaluation utilizing the ARRAY™ Tablet app. Certificates will be emailed within two weeks. There is no fee to participate in the activity or for the generation of the certificate.
For questions please contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.